Novel approaches to using PDE4 inhibitors for antihypertensive therapy.
Phosphodiesterase (PDE)4 inhibitors are effective vasodilators. In addition to the treatment of asthma and other inflammatory diseases, such as chronic obstructive pulmonary disease, wide-spectrum PDE4 inhibitors may also be developed for use in antihypertensive therapy, especially in patients with impaired renal function and elevated pulmonary arterial pressure. Rational approaches to overcoming the intrinsic emetogenic response associated with PDE4 inhibition are discussed, and a dual-action drug development that incorporates L-type Ca2+ channel antagonism and selective PDE4 inhibition is proposed. The potential for research and development of such a dual-action agent should eventually provide healthcare professionals with a new category of therapeutic options with which to attempt to combat hypertension.
Wang
Desuo
D
College of Pharmacy, University of South Carolina, 700 Sumter Street, Columbia, SC 29208, USA. wang@cop.sc.edu
Wang
Ting
T
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry / Q000627:therapeutic use*; D020746:Calcium Channels, L-Type / Q000187:drug effects; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004359:Drug Therapy, Combination; D006801:Humans; D014665:Vasodilator Agents / Q000737:chemistry / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control
D000959:Antihypertensive Agents; D020746:Calcium Channels, L-Type; D014665:Vasodilator Agents; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4